子宫内膜异位症与子宫腺肌症患者卵巢癌发病率均升高
基于荷兰病理数据库(1990-2015)的队列研究,组织学确诊子宫内膜异位症(51,544例)和/或子宫腺肌症(85,015例)女性与良性皮肤痣女性(132,654例)匹配,评估卵巢癌发病率。子宫内膜异位症和子宫腺肌症队列年龄调整IRR分别为19.75(95%CI 16.70-23.35)和5.93(95%CI 4.91-7.16),以子宫内膜样和透明细胞亚型最高。排除随访第一年后,子宫内膜异位症队列透明细胞癌IRR 3.92(95%CI 2.19-7.01)、子宫内膜样癌IRR 2.39(95%CI 1.28-4.45);子宫腺肌症队列子宫内膜样癌IRR 2.51(95%CI 1.29-4.90)。
要点
- 组织学确诊子宫内膜异位症者卵巢癌年龄调整IRR 19.75,子宫腺肌症者IRR 5.93。
- 最高IRR见于子宫内膜样和透明细胞卵巢癌亚型。
- 排除随访第一年,两队列子宫内膜样癌及内异症队列透明细胞癌IRR仍显著升高。
核心结论
- 组织学确诊的子宫内膜异位症和子宫腺肌症均与卵巢癌发病率升高相关,子宫内膜异位症升高幅度最大。
研究设计与样本
- 荷兰病理数据库(1990-2015)队列研究,纳入组织学确诊子宫内膜异位症51,544例、子宫腺肌症85,015例,匹配良性皮肤痣女性132,654例。
主要发现
- 子宫内膜异位症、子宫腺肌症和痣队列卵巢癌病例数分别为1017例(2.0%)、1284例(1.5%)和471例(0.4%)。
- 年龄调整IRR:子宫内膜异位症队列19.75(95%CI 16.70-23.35),子宫腺肌症队列5.93(95%CI 4.91-7.16)。
- 最高IRR见于子宫内膜样和透明细胞卵巢癌亚型。
- 排除随访第一年,子宫内膜异位症队列透明细胞癌年龄调整IRR 3.92(95%CI 2.19-7.01)、子宫内膜样癌IRR 2.39(95%CI 1.28-4.45)。
- 排除随访第一年,子宫腺肌症队列子宫内膜样癌年龄调整IRR 2.51(95%CI 1.29-4.90)。
临床怎么用
- 妇科医生应意识到子宫腺肌症女性卵巢癌发病率亦升高。
- 对子宫内膜异位症和子宫腺肌症女性,尤其关注子宫内膜样和透明细胞卵巢癌亚型风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Assessing the association between endometriosis and/or adenomyosis and ovarian cancer. METHODS: We identified all women with histological proven endometriosis (51,544 women) and/or adenomyosis (85,015 women) from the Dutch pathology database (1990-2015) and matched with women with a benign dermal nevus (132,654 women). Histology results for ovarian cancer were retrieved. We estimated crude and age-adjusted incidence rate ratios (IRR) for ovarian cancer. RESULTS: We found 1017 (2.0%), 1284 (1.5%) and 471 (0.4%) ovarian cancer cases in the endometriosis, adenomyosis and nevus cohort, respectively. The age-adjusted IRRs were 19.75 (95% CI 16.70-23.35) in the endometriosis cohort and 5.93 (95% CI 4.91-7.16) in the adenomyosis cohort. The highest IRRs were found for endometrioid and clear cell ovarian cancer subtypes. Excluding the first year of follow-up did not result in a significant IRR for ovarian cancer overall but resulted in a statistically significant age-adjusted IRR of 3.92 (95% CI 2.19-7.01) for clear cell ovarian cancer and 2.39 (95% CI 1.28-4.45) for endometrioid ovarian cancer in the endometriosis cohort. Additionally, we found a statistically significant age-adjusted IRR of 2.51 (95% CI 1.29-4.90) for endometrioid ovarian cancer in the adenomyosis cohort. CONCLUSION: We found an increased ovarian cancer incidence in both histological proven endometriosis and adenomyosis. This increased incidence was largest for endometriosis. Excluding the first year of follow-up resulted in an increased incidence for endometrioid ovarian cancer in both cohorts and clear cell ovarian cancer in the endometriosis cohort. This study shows that gynecologist should also be aware of an increased ovarian cancer incidence in women with adenomyosis.
引用
- Hermens M, van Altena AM, Bulten J, et al. Increased incidence of ovarian cancer in both endometriosis and adenomyosis. Gynecol Oncol. 2021. PMID: 34266690. doi:10.1016/j.ygyno.2021.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。